Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kouji Hirota has a total of 185 co-authors. Here are the top co-authors by number of shared publications:

  • Takuya Abe

    Division of Biochemistry, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, 981-8558, Japan

    14 shared publications
  • Ryotaro Kawasumi

    Department of Chemistry, Graduate School of Science, Tokyo Metropolitan University, Minamiosawa 1-1, Hachioji-shi, Tokyo 192-0397, Japan

    11 shared publications
  • Shunichi Takeda

    Shenzhen University School of Medicine, Shenzhen, China

    11 shared publications
  • Masato Ooka

    Department of Chemistry, Graduate School of Science Tokyo Metropolitan University Tokyo Japan

    9 shared publications
  • Satoshi Senmatsu

    Department of Chemistry, Graduate School of Science, Tokyo Metropolitan University, Hachioji-shi, Tokyo, Japan

    9 shared publications
  • Ryotaro Kawasumi

    Department of Chemistry, Graduate School of Science, Tokyo Metropolitan University, Minamiosawa 1-1, Hachioji-shi, Tokyo 192-0397, Japan

    7 shared publications

Latest Publications

  • Open Access

    Dual regulation of transcription factor binding by tup11/12-mediated destabilization and DNA loop-mediated stabilization ensures stress-specific gene activation in fission yeast

    by Yusuke Tsuruta, Hirotaka Inoue, Kenta Hagiwara, Charles S Hoffman, Kouji Hirota

    An appropriate transcriptional response to external stresses is crucial for all organisms. Gene expression is regulated by transcription factors (TFs) binding to specific DNA cis-elements. However, how individual TFs achieve stress-specific binding remains elusive. Here we examine the molecular basis of the stress-specific transcriptional response of the Schizosaccharomyces pombe fbp1 gene. The fbp1 gene is activated upon glucose starvation, with transcriptional co-repressors Tup11 and Tup12 playing pivotal roles in maintaining stress-specificity. In the absence of Tup11 and Tup12, nonspecific activation of fbp1 transcription occurs, which requires the TFs Atf1 and Rst2—both essential for fbp1 induction. Moreover, this aberrant fbp1 activation is diminished by the loss of Php5, a factor indispensable for DNA-loop formation between Atf1- and Rst2-binding sites. The defective nonspecific transcription in the tup11∆/tup12∆/php5∆ mutant is restored when Atf1- and Rst2-binding sites are artificially positioned in proximity to each other, indicating that reciprocal stabilization between these TFs facilitates their binding. These findings demonstrate that fbp1 achieves stress-specific transcriptional activation through the counteractive regulation of TF-binding: Tup11/12-mediated destabilization and DNA loop-mediated stabilization. The synergistic reduction in stress tolerance observed in the tup11∆/tup12∆/php5∆ mutant further suggests that this dual regulatory mechanism is crucial for cellular adaptation to environmental stresses.

  • Open Access

    PARP1 safeguards nascent DNA from SMUG1-dependent processing of incorporated 5-hydroxymethyl-2′-deoxyuridine

    by Rubaiat E Tabassum, Kouji Hirota, Ryotaro Kawasumi

  • Open Access

    Common DNA Damage Response Factors Required for Cellular Resistance to Inhibitors for the Ataxia Telangiectasia and Rad3-Related Checkpoint Kinase in Hematopoietic Cells

    by Muhammad Tufail, Ryotaro Kawasumi, Sangita Dattatray Shinde, Sivapriya Kirubakaran, Kouji Hirota

    Targeting checkpoints is one of the most promising strategies in cancer chemotherapy. Leukemia, in particular, is expected to yield high therapeutic efficacy due to its high replication stress. However, the DNA damage response factors involved in the vulnerability to checkpoint inhibitors of these hematopoietic cancers remain elusive. In this study, we reveal common factors required for cellular resistance to ATR inhibition in hematopoietic cancer cells. We explored the DNA damage response pathways contributing to cellular tolerance to three types of ATR inhibitors using an isogenic DNA repair factor mutant collection derived from the chicken lymphoma cell line, DT40. We first demonstrated significant ATR inhibition activity of the recently developed Torin2 analogous compounds, SPK67 and SPK98, under stressed replication conditions. We then compared cellular sensitivity patterns of the known ATR inhibitor, VE-821, and the potential ATR inhibitors, SPK67 and SPK98, in 24 types of mutants deficient in genome maintenance systems and found that RAD17/−, FEN1−/−, and POLB−/− cells exhibited hypersensitivity to all these drugs. Consistently, these mutant cells exhibited increased chromosome instability upon treatment with VE-821, SPK67, and SPK98, resulting in apoptosis. These results suggest that Rad17, Fen1, and Polymerase β play roles in responding to DNA damage caused by these drugs. However, ATR inhibition did not result in cell-cycle arrest, Chk1 phosphorylation, or increased γH2AX levels. These results suggest that, although ATR inhibition causes DNA damage, impaired checkpoint function suppresses the appropriate activation of DNA damage signaling pathways, thereby leading to cell death. This study is the first to demonstrate the importance of Rad17, Fen1, and Polymerase β in cellular tolerance to ATR inhibition in hematopoietic cells.

  • Open Access

    Generation of Human Haematopoietic Model Cell Lines Revealed Distinct Replication Stress Tolerance Between Two Oncogenic KRAS Mutations, G12V and A146T

    by Mone Okuda, Ryotaro Kawasumi, Kayoko Tanaka, Kouji Hirota

    KRAS is one of the most frequently mutated genes in all human cancers, and its oncogenic mutation hotspots are glycine 12 (G12), glycine 13 (G13), glutamine 61 (Q61) and alanine 146 (A146). Among these hotspot mutations, A146 substitution mutations (A146X) occur relatively infrequently, except for haematopoietic and lymphoid cancers, suggesting that A146X causes intrinsically distinct KRAS signalling compared to other KRAS oncogenic alleles. However, due to the absence of model A146X cell lines derived from haematopoietic sources, the cellular mechanisms that cause the differences between KRAS.A146X and other common KRAS mutants, such as KRAS.G12X, remain largely unexplored. In this study, we developed a set of isogenic model haematopoietic cell lines expressing KRAS.A146T, KRAS.G12V and KRAS.G12G (non-mutated) from the endogenous locus by genetically modifying the human lymphoblastoid TK6 cell line. We found that TK6 cells carrying KRASA146T/+ or KRASG12V/+ exhibited increased replication stress compared to KRAS wild-type cells. Strikingly, KRASA146T/+ cells strongly rely on PrimPol for maintaining cellular survival upon replication stress. In contrast, KRASG12V/+ cells exhibited hypersensitivity to inhibitors for the ATR-Chk1 checkpoint signalling axis and to nucleoside analogues commonly used to treat cancers and viral infections. Our findings demonstrate that the endogenously expressed oncogenic KRAS mutations exacerbate the replication stress and reveal KRAS allele-specific replication phenotypes, facilitating the development of effective chemotherapies tailored to specific oncogenic KRAS mutation alleles and types of cancer. Moreover, our study offers valuable model cell lines for investigating mechanisms underlying replication vulnerability in cancers harbouring oncogenic KRAS mutations.


  • Open Access

    Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

    by Ryotaro Kawasumi, Rubaiat E. Tabassum, Kouji Hirota

    Conventional cancer therapies, including radiation therapy and chemotherapy, rely on inflicting DNA damage, yet they inevitably affect normal cells, leading to severe adverse effects. The advent of precision chemotherapy exploiting tumor‐specific DNA repair defects has validated the effectiveness of this approach. The first successful example is PARP inhibitors, which selectively kill homologous recombination (HR) defective cancers, such as familial breast cancer possessing HR deficiency due to BRCA gene mutations. However, the broader landscape of DNA maintenance—including DNA replication, repair, and checkpoint pathways—harbors numerous mutations in tumors that remain untargeted. Here, we propose repurposing chain‐terminating nucleoside analogs (CTNAs) to target such cancers' vulnerabilities. CTNAs, long utilized as anti‐cancers and anti‐viral drugs, inhibit replication and thereby suppress growth, but their activity has never been systematically aligned with specific cancer mutations associated with DNA maintenance defects. Based on our recent studies, we demonstrate that CTNAs elicit synthetic lethality in cells deficient for distinct DNA maintenance systems, amplifying replication stress, leading to cell death. We highlight the spectrum of CTNA‐induced lesions and repair pathways required for cellular tolerance. This framework presents a versatile “repair‐defect‐guided” chemotherapy that expands the clinical utility of CTNAs and improves therapeutic effect by reducing side effects.


  • Open Access

    Proofreading exonuclease activities of Polδ and Polε differentially contribute to the removal of chain-terminating nucleoside analogs

    by Eri Nishizawa, Hiromori Ohkubo, Ryotaro Kawasumi, Masataka Tsuda, Kouji Hirota


  • Open Access

    The flap endonuclease-1 promotes cellular tolerance to a chain-terminating nucleoside analog, alovudine, by counteracting the toxic effect of 53BP1

    by Bayejid Hosen, Ryotaro Kawasumi, Kouji Hirota

    Chain-terminating nucleoside analogs (CTNAs) are frequently used as antiviral and anticancer agents. CTNAs are incorporated into the end of nascent DNA during DNA synthesis and inhibit subsequent DNA polymerization, thereby restricting the proliferation of viruses and cancer cells. Alovudine, a thymidine analog, exerts chain-termination effects and is used as an antiviral drug. However, the mechanisms underlying cellular tolerance to alovudine have not been fully elucidated. Here, we show that flap endonuclease-1 (Fen1) and p53 binding protein-1 (53BP1) counteractively mitigate the chain-terminating effect of alovudine. We found that the cells deficient in Fen1 (FEN1−/−) showed stronger chain-terminating effects of alovudine with augmented DNA damage than wild-type cells, leading to their alovudine hypersensitivity. Moreover, we found that the Okazaki fragment maturation was critically slowed in FEN1−/− cells when cells were challenged with alovudine. Remarkably, the loss of 53BP1 rescued these phenotypes. We found that 53BP1 formed sub-nuclear foci upon alovudine treatment and these 53BP1 foci were critically increased in FEN1−/− cells, indicating that Fen1 suppresses alovudine-mediated toxic 53BP1 subnuclear foci thereby promoting Okazaki fragment maturation and suppressing DNA damage. In this study, we uncovered the previously unappreciated role of Fen1 in the suppression of toxic action of 53BP1 at alovudine-incorporated Okazaki fragment.